Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I wouldn’t be surprised if there is another Paulson raise. If you are an accredited investor, you can contact their offices to see if you can participate. I’m sure an NDA will need to be signed though.
A hopium story by bringing on one of the foremost doctors in breast cancer research in the world??
Righhhtttttt
I didn’t particularly like it either and I interpreted it as sub 70%. However, I’m confident that the 700mg dose will push it above and beyond 70%. I believe that in early animals models, animals were given much higher HED than 700mg and no anti-bodies/SAEs were observed which is very important. The one thing this does is it adds further delay to the mono trial which is the part I’m not thrilled with.
(Im)patiently waiting...
I don’t believe it to be either. I think it was likely because of certain material events associated with the company, specifically Dr. Pestell coming aboard. My original point was, that aside from a few people calling this a “pump and dump stock”, most everyone on this board knows what kind of a rare drug Pro-140 is. No SAEs, no known antibodies, and strong potential for multiple multi-billion dollar applications. Honestly, how many drugs compare that favorably to Pro-140? Let alone, what drugs simply have that safety profile. With science that compelling, why hasn’t this been moved on yet? Drugs with far less potential are being gobbled up by BP.
That needed more context. I meant in the sense of a pump and dump stock. Not an event that creates a pump and dump to a stock. The recent price action could very well be attributed to the SA article.
I wouldn’t expect him to come out and signal disaster. Nader is the CEO, so he has to have a good poker face regardless of positive or negative developments. I hope the financing is figured out.
I’m optimistic because Pro-140 is a rare drug (no SAE, no anti-bodies shown to date) that has multiple billion dollar applications. I’m still nervous regarding the financing though.
Still (im)patiently waiting..
With the cash on hand they have left, we’ll have to hear something soon.
The tune changes when the company outlook changes. Company outlook right now has more delays due to uncertainty with regard to financing. If you ask anyone who regularly participates on this board, outside of a few id**ts who call this a pump and dump, no one will dispute the science behind Pro-140.
Personally, the 10K has me worried. They need money to keep the lights on. T0m did make an interesting point that Dr. Pestell wouldn’t join unless there was some known direction regarding financing the company. However, I know Dr. Pestell’s science prowess - I don’t know his business prowess. It’s not unreasonable to question the direction of the company when we’re faced with huge financing issues.
Ideally, the next raise will come from a partner who understands the potential of Pro-140 and won’t dump all of their shares for a quick turnaround. Ideally...
Here’s to hoping that Nader can bag a big sum of cash and not another small raise.
I believe the same with regard to financing. Science is already a given for me at this point. If they can get enough money to ensure lights stay on through till the end of mono development - I believe this thing will be in the bag.
(Im)patiently waiting...
You’re more eloquent than I am. My thoughts exactly.
I am not a doctor, but I am more of a clinical mind than I am of a business mind. That is why I am an investor and not a trader.
When Dr. Pestell came aboard, it brought my enthusiasm to a new height. As enthuiastic as I am though, I am still skeptical. So just know, not all skepticism brings ulterior motives.
Personally, I think Pro-140 is a multi-billion dollar drug in the combo field. But ‘value’ is a funny word. Value isn’t what something is worth; rather, it is the maximum price someone is willing to pay for something.
Looking at TaiMed’s SP, it didn’t appreciate to that level until it was close to approval. Again, I look for a similar appreciation in SP with CYDY leading up to combo approval, if not sooner..
Those were Saltzs’ (not verbatim) words, not mine. I was using that as an example that even the biggest supporters can be skeptical - and should be. It’s the healthy skepticism and playing devils advocate which helps us make informed decisions.
As for Ibalizumab, that is an FDA approved drug. Pro-140 is not. However, if/when Pro-140 becomes approved for combo therapy, I think this thing will sail (if not sooner).
Did it go from .44 to .65 because of Finesand’s “pump” or because the company announced that they are bringing one of the foremost doctors in world in the field of breast cancer aboard? I’m not knocking you for being skeptical - I just view it as unlikely.
So why hasn’t CYDY been bought out yet? Pro-140 has clearly demonstrated its efficacy in the combo realm as well as a high likelihood (IMO) that it can be used in HIV monotherapy and GVHD as well. Not to mention a half dozen other potential applications. BP has bought out dozens of companies which has FAR inferior drugs/pipelines. It’s completely safe as well! So why hasn’t BP come in and snatched this thing up? Is it because of potential patent expiration’s? Not being fully proven as a mono drug? BP believes CYDY won’t have enough financing to get to the finish line? I think these are all reasonable questions. Even Saltz (long time investor and one of the biggest proponents of Pro-140) mentioned he doesn’t believe Pro-140 holds much value as a combo drug to BP.
I am of a similar mindset as you though. It’s not a matter of if, but when this gets bought out.
All that due diligence and effort just to flip a .50-.70c stock that has low volume? Doubt it. I believe Finesand raises plenty of legitimate questions that could affect the overall value of the company. Just my thoughts.
I think Pearsby made a new account lol
I just wanted to say I appreciate all of you and your teams balanced due diligence relating to CytoDyn.
Are you speculating on the end game on the company? If so, I would like to know what you personally think will happen in the end.
The raise I participated in had a restriction. I’m not sure about some of the most recent Paulson raises however.
I participated in a Paulson raise 2.5+ years ago. I sold a small portion of my shares over a year ago, but I’m still holding the vast majority of my shares and all my warrants.
If we uplist to another exchange, warrants have to be exercised or dumped by the holder if I’m not mistaken. Outside of that, I don’t believe the company can ‘force’ any warrant conversion. They did incentive conversion recently by lowering the strike price which I did not take advantage of. However; I did like that as a means to try and raise money while avoiding further dilution. If we can somehow approach $2 organically, I will be exercising my warrants.
As I understand it, the SOC is established by a consensus from a group of experts on the condition. We currently have multiple experts in the field of HIV touting Pro-140. Based on the clinical data, I feel Pro-140 will eventually be the SOC for CCR5 tropic HIV patients.
I agree with you that Dr. Pestell cannot immediately change the valuation of our company and we need more clinical data on the other non-HIV indications. However, Dr. Pestell is THE guy in the breast/prostate cancer field. That’s why I said I think we need to pull in the funds to show we can stay open to develop this drug further. I don’t think $30+/share is a today or tomorrow buyout figure based on what we can prove the drug does. But I believe that it’s possible and am confident that it will prove itself to be just that.
Lofty - maybe.
IMO Pro-140 will prove itself as a monotherapy treatment and replace the SOC for CCR5 HIV patients. That alone is a 10+ billion dollar market (not to mention a threat to the current SOC which arguably gives it more value).
Pharmacyclics produced a product that cured a disease state which limits its revenue potential obviously as the number of potential patients will drastically reduce. Pro-140 isn’t a 1 trick pony either. We’re talking multiple indications with most of them being billion dollar markets. If we can get the funds to show we can stay open for continued development for the next year, I think $30+ is very possible as an end game.
P.S. I work with multiple doctors (a couple oncology doctors) and they are very familiar with Dr. Pestell and know him to be the real deal. I was always a huge believer in the drug before, but over the course of the past couple weeks I’m even more excited, if that’s possible.
If this thing can organically raise its SP to close to $2, this thing is done. Myself and other warrant holders will start exercising them which will give this company enough money to fund the rest of their PIII trials. There’s momentum to this girl right now and I’m hoping for a couple surprising PRs in the near future to get her there. If you’re on the sidelines for this, you’ll be incredibly disappointed to put it lightly. I’m looking for $30+/ too.
I’m not debating that’s what PRO-140 is worth - but at $33/share, that is currently about a $12B buyout. What are the total list of companies that have that type of capital AND would be willing to spend that?
More excellent news regarding, yet another, possible application for this biologic!
I hope they have more good news/PRs lines up or this temporary SP appreciation will be moot.
When I went through Paulson, my deal included warrants that have 5 years until they expire. I know there were raises with warrants before I jumped in with the same expiration.
My question is: does anyone know how many warrants are set to expire in the next 6-12 months?
I participated in a Paulson raise and that’s exactly how the reps sell the benefit of the offering (even if the company/product does not pan out). Invest your money, sell your shares near the IPO price, and keep the warrants risk free for when/if the stock soars. I’ve sold a small portion of my shares, but kept the vast majority of them. Others have been following paulsons pitch and dumping their shares and keeping the warrants. Very likely that this is contributing to suppressed share price.
Such a weird run up at the end of today. Is this a mini short squeeze or is there something else at bay?
Normally you would think so. However, I think these funds eliminate the risk/concern of having to fund the trials. Thus, I actually see this as very positive news and the market had almost 2 hours to react to it as well. Granted, it decreases the return investors will make from the company, but that was to be expected with a pre-revenue biotech.
I would gladly pay you a dollar to go away.
Not surprising for someone who can't differentiate between something anecdotal and science.
Saltz- as a warrant holder as well, I am unlikely to convert them given the potential upside of the stock. I am an investor and am not looking for a quick flip of shares at a small premium.
As someone who participated in one of Paulsons private placements, considered investing in another, and a holder of warrants, I had to sign multiple NDAs. Not that I can disclose what information was/wasn't given to me, (because, you know, I signed an NDA), but I think it's certainly very possible with regard to your assessment that some individuals may have been given more information than others. That's pure speculation on my part and we'll just have to wait to see how this plays out.
Anecdotal evidence is based on hearsay rather than hard facts. 11 people have been on PRO-140 monotherapy treatment for more than 2 years with completely suppressed viral loads. That's not subjective - that's objectively proven with clinical testing.
What's SAD is your attempt to mislead people about PRO-140 with your posts.
You say it is not science until large scale evidence produces validity for efficacy and safety. That's not what science is, that's the FDA requirements for approval of a drug. You might want to revisit the definition of science as well.
You keep saying these scientific results are anecdotal. Perhaps you need to revisit the definition of anecdotal. Don't worry, I got you:
Anecdotal - based on personal observation, case study reports, or random investigations rather than systematic scientific evaluation.
This isn't based on personal observation. The patient was injected with PRO-140 and their viral loads are now undetectable. There are also a dozen more people who are on PRO-140 as a monotherapy with completely suppressed viral loads. This was found with laboratory testing. That's not anecdotal, that's science.
I think it speaks more towards managements ineptitude to present at the conference.
Conference is cancelled due to the California fires.
Yes, my mistake. 12/6 @ 4:30.
I would be shocked if they do not come then.
We present at the LD Micro tomorrow at 4:30. Results come then?